羟考酮
医学
类阿片
(+)-纳洛酮
麻醉
便秘
不利影响
内科学
受体
作者
Karen H. Simpson,Petra Leyendecker,Michael Hopp,S Müller-Lissner,O. Löwenstein,Jose De Andrés,J. Troy Ferrarons,B. Bosse,B. Krain,Tara Nichols,Walter K. Kremers,Karen Reimer
标识
DOI:10.1185/03007990802584454
摘要
Opioid therapy is frequently associated with treatment-limiting constipation. Naloxone is an opioid antagonist with low oral systemic bioavailability. This Phase III clinical trial assessed the safety and efficacy of an oral fixed-ratio combination of oxycodone prolonged-release (PR) and naloxone PR compared with oxycodone PR in relieving opioid-induced constipation.This double-blind, multicenter trial was conducted in specialist and primary care centers in four European countries in an out-patients setting. The study included 322 adult patients with moderate-to-severe, noncancer pain requiring opioid therapy in a range of >or=20 mg/day and
科研通智能强力驱动
Strongly Powered by AbleSci AI